---
title: "Stifel Nicolaus Sticks to Their Buy Rating for Disc Medicine (IRON)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285910632.md"
description: "Stifel Nicolaus analyst Stephen Willey has reaffirmed a Buy rating for Disc Medicine (IRON), setting a price target of $111.00. Willey, a 4-star analyst with a 44.44% success rate, focuses on the Healthcare sector. The consensus for Disc Medicine is a Strong Buy, with an average price target of $97.67 according to TipRanks."
datetime: "2026-05-11T08:56:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285910632.md)
  - [en](https://longbridge.com/en/news/285910632.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285910632.md)
---

# Stifel Nicolaus Sticks to Their Buy Rating for Disc Medicine (IRON)

In a report released today, Stephen Willey from Stifel Nicolaus maintained a Buy rating on Disc Medicine, with a price target of $111.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Willey is a 4-star analyst with an average return of 9.6% and a 44.44% success rate. Willey covers the Healthcare sector, focusing on stocks such as Disc Medicine, Incyte, and Insmed.

Disc Medicine has an analyst consensus of Strong Buy, with a price target consensus of $97.67.

### Related Stocks

- [IRON.US](https://longbridge.com/en/quote/IRON.US.md)
- [SF.US](https://longbridge.com/en/quote/SF.US.md)
- [INCY.US](https://longbridge.com/en/quote/INCY.US.md)
- [INSM.US](https://longbridge.com/en/quote/INSM.US.md)
- [SF-C.US](https://longbridge.com/en/quote/SF-C.US.md)
- [SFB.US](https://longbridge.com/en/quote/SFB.US.md)
- [SF-B.US](https://longbridge.com/en/quote/SF-B.US.md)
- [SF-D.US](https://longbridge.com/en/quote/SF-D.US.md)

## Related News & Research

- [Disc Medicine (IRON) Projected to Post Earnings on Thursday](https://longbridge.com/en/news/284706493.md)
- [Disc Medicine, Inc. (NASDAQ:IRON) Receives Consensus Rating of "Moderate Buy" from Brokerages](https://longbridge.com/en/news/270374422.md)
- [LifeSci Capital Sticks to Its Buy Rating for Neurogene (NGNE)](https://longbridge.com/en/news/286648209.md)
- [LifeSci Capital Sticks to Their Buy Rating for MoonLake Immunotherapeutics (MLTX)](https://longbridge.com/en/news/286649191.md)
- [Stifel Just Raised Its Price Target on Palo Alto Networks. Here's Why.](https://longbridge.com/en/news/287118503.md)